Wall Street analyst estimates for Mereo BioPharma Group plc (MREO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.62 |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -0.33 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | -$3.3M | 0 | 0 | 0 | $49.2M | 0 | $10.0M | 0 | $500000 |
| Cost of Revenue | $24.6M | $34.6M | $22.7M | $2.0M | $2.1M | $24.2M | -$1.1M | $2.6M | 0 | $133000 |
| Gross Profit | -$24.6M | -$37.9M | -$22.7M | -$2.0M | -$2.1M | $25.0M | $1.1M | $7.4M | 0 | $367000 |
| Research & Development | $24.6M | $34.6M | $22.7M | $30.1M | $21.0M | $31.8M | $29.5M | $17.4M | 0 | $17.8M |
| Selling, General & Admin | $11.6M | $10.7M | $12.5M | $18.3M | $25.2M | $21.5M | $26.1M | $18.4M | 0 | $23.0M |
| Operating Expenses | $11.6M | $10.7M | $12.5M | $48.4M | $46.1M | $53.3M | $55.6M | $35.8M | 0 | $38.6M |
| Operating Income | -$36.2M | -$45.3M | -$35.2M | -$50.4M | -$48.2M | -$28.3M | -$54.4M | -$28.4M | 0 | -$38.3M |
| EBITDA | -$38.4M | -$44.4M | -$34.9M | -$44.6M | -$203.4M | $25.5M | -$37.9M | -$26.1M | 0 | -$40.5M |
| Interest Expense | $179765 | $1.1M | $2.4M | $3.5M | $6.4M | $5.2M | $4.2M | $2.9M | 0 | $255000 |
| Pre-tax Income | -$33.7M | -$47.0M | -$37.3M | -$52.5M | -$213.4M | $19.2M | -$42.9M | -$30.0M | 0 | -$41.9M |
| Income Tax | -$5.3M | -$8.2M | -$5.3M | -$8.0M | -$3.6M | $2.0M | -$718000 | -$532000 | 0 | 0 |
| Net Income | -$28.4M | -$38.8M | -$32.0M | -$44.5M | -$209.8M | $17.2M | -$42.2M | -$29.5M | 0 | -$41.9M |
| EPS | $-19553.91 | $-19003.80 | $-14352.87 | $-12902.58 | $-16503.30 | $749.65 | $-1.80 | $-1100.22 | $0.00 | $-0.26 |
| EPS (Diluted) | $-19553.91 | $-19003.80 | $-14352.87 | $-12902.58 | $-16503.30 | $749.65 | $-1.80 | $-1100.22 | $0.00 | $-0.26 |
| Shares Outstanding (Diluted) | $9.0M | $13.8M | $14.2M | $17.9M | $67.8M | $116.7M | $22.8M | $131.9M | 0 | $159.4M |
Price
| Price | $0.27 |
| Market Cap | $42M |
| Exchange | NASDAQ |
| Country | GB |
Related companies: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of MREO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks